Evrom Cannalytech
Cannabis-Specific Biostimulants Enhancing Yield and Disease Resistance
Company Overview
Snapshot
Founded in February 2023 by Onie Tsabari, Evrom Cannalytech operates with 1–10 employees. The company is currently in its Pre-Funding stage, focusing on the development of patent-pending biostimulants designed to enhance cannabis cultivation.
Business overview
Evrom Cannalytech specializes in developing biostimulants specifically for cannabis cultivation. Their patent-pending formulations are engineered to boost disease resistance and increase the production of cannabinoids and terpenoids in both greenhouse and outdoor environments. By leveraging pathogen-derived compounds, these biostimulants activate the plant's natural defense mechanisms, promoting healthier growth and improved yields. The company operates within the Agriculture & Food Technologies sector, with a focus on Ag Tech, Genetics & Input, and Medical Cannabis markets.
Log in to access full profile ›Company Intelligence Q&A
- What is Evrom Cannalytech's core product offering?
- Evrom Cannalytech develops cannabis-specific biostimulants with patent-pending formulations designed to enhance disease resistance and increase cannabinoid and terpenoid production in cannabis plants.
- When was Evrom Cannalytech founded and by whom?
- Evrom Cannalytech was founded in February 2023 by Onie Tsabari.
- What is the primary sector Evrom Cannalytech operates in?
- Evrom Cannalytech's primary sector is Agriculture & Food Technologies, with a specific focus on Ag Tech and Medical Cannabis.
- What is the current employee size of Evrom Cannalytech?
- Evrom Cannalytech currently has 1–10 employees.
- What is the strategic goal of Evrom Cannalytech's biostimulants?
- The strategic goal of Evrom Cannalytech's biostimulants is to activate the plant's defense mechanisms using pathogen-derived compounds, leading to healthier growth and improved yields in cannabis cultivation.